{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964647",
  "id": "02964647",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250701",
  "time": "1657",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06lbrckkc6stzy.pdf",
  "summary": "**Appendix 3Y Summary (Change of Director\u2019s Interest Notice - Chimeric Therapeutics Limited, ASX: CHM)**  \n\n- **Director**: Lesley Russell  \n- **Date of Change**: 26 June 2025  \n- **Change Details**: Expiry of 2,750,000 unlisted options (direct interest). No securities acquired/disposed for cash consideration.  \n- **Post-Change Holdings**: 1,739,130 shares (direct), zero options remaining.  \n- **Closed Period Trading**: No trading during closed period.  \n\n**No material trading or capital markets impact identified** (routine director interest update).",
  "usage": {
    "prompt_tokens": 1068,
    "completion_tokens": 131,
    "total_tokens": 1199,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-01T07:16:33.560265"
}